comprehensive -WSS

comprehensive

author：leisure time 2025-09-27 19:29:06 - browse：332

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： CEOs share strategies for surviving biotech slump

focus

WSS

HHS leader on health, climate change and biopharma emissions

The explosion of genetic testing requires a new approach

The EU Joint Clinical Assessment needs to live up to its promise

Doctors are clamoring for more clarity on Paxlovid prescribing

Studies point to risks of excluding people with obesity from drug trials

STAT Summit: Michael J. Fox on progress in Parkinson's research

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Wildfire smoke exposes gaps in outdoor worker protections

UnitedHealth’s board chair also owns a personal investment firm

Psychedelics group wrestles with new pharma identity

Senate committee scrutinizes Medicare Advantage brokers

Wildfire smoke exposes gaps in outdoor worker protections

Doctors push to include dialysis machines in emergency stockpile

Duchenne breakthrough therapy leaves behind pioneering families

Sage considers ways to reduce costs following FDA rejection

Medicare proposal to cover medical devices draws a mixed reaction

Google's generative AI to analyze medical images — and talk to docs

knowledge

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Studies point to risks of excluding people with obesity from drug trials

FDA warns J&J's Abiomed: We will regulate your software

Pharmacists can make shortage drugs, but at what cost?

Restaurant meals are packed with calories, and we still keep eating them

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

focus

entertainment

hotspot

hotspot